Strides Expands Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib – Targeting $116M Market Opportunity
In a strategic move to further strengthen its footprint in the anti-inflammatory therapeutic segment, Strides Pharma Science Limited announced that […]
